Gabriela Beraja

Dr. Gabriela Beraja


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
SGSimonetta Ines Gaumond
Simonetta Ines Gaumond
GBGabriela Beraja
Gabriela Beraja
IKIsabella Kamholtz
Isabella Kamholtz
LFLina M Ferrari
Lina M Ferrari
RMRami H. Mahmoud
Rami H. Mahmoud
JJJoaquín J. Jiménez
Joaquín J. Jiménez
Background/Objectives: Ovarian cancer is the fifth most common cancer among women, with an estimated 19,680 new cases projected in 2024. Adjuvant chemotherapy remains the standard treatment for epithelial ovarian cancers but is frequently associated with adverse events, such as chemotherapy-induced alopecia (CIA). CIA is a particularly distressing side effect that significantly affects the body image, self-esteem, and quality of life of patients. Unfortunately, CIA remains underexplored in patients with ovarian cancer. Methods: This scoping review analyzed PubMed- and EMBASE-indexed studies investigating the incidence, severity, and mechanisms of CIA in ovarian cancer patients. Eighteen studies were included for analysis. Results: Our analysis identified platinum-based compounds, taxanes, and topoisomerase I inhibitors as the agents most strongly correlated with severe alopecia, particularly in combination regimens such as carboplatin–paclitaxel (CP), and cyclophosphamide, adriamycin, and cisplatin (CAP). Among the monotherapies, taxanes, including paclitaxel and docetaxel, posed the highest risk of CIA. Mild-to-moderate alopecia was observed in patients treated with gemcitabine or pegylated liposomal doxorubicin. Alternative factors such as dosing schedules and prior chemotherapy exposure also significantly influence CIA severity. Conclusions: Given the profound psychosocial impact of CIA, optimizing treatment protocols to reduce the severity of alopecia without compromising therapeutic efficacy is crucial. These findings offer insights that may guide future therapeutic strategies for improving patient outcomes and quality of life.

7 March 2026 in Cancers
Verified
Journal Article
Open access
PDF file
SGSimonetta Ines Gaumond
Simonetta Ines Gaumond
SSSophie Shrestha
Sophie Shrestha
IKIsabella Kamholtz
Isabella Kamholtz
GBGabriela Beraja
Gabriela Beraja
JJJoaquín J. Jiménez
Joaquín J. Jiménez
Chemotherapy-induced alopecia (CIA) is one of the most common and visible toxicities of breast cancer treatment, yet its true incidence, severity, and long-term outcomes remain inconsistently reported. Although CIA is frequently cited as affecting approximately 65% of patients and persistent alopecia has historically been considered uncommon (1–15%), emerging data suggest a substantially greater burden. We conducted a scoping review of PubMed, EMBASE, SCOPUS, and Cochrane databases to synthesize regimen-specific evidence on the incidence, severity, and persistence of CIA in breast cancer patients. Anthracycline- and taxane-based regimens were associated with the highest risk, with severe alopecia reported in more than 70% of patients and rates approaching 90–100% in combination regimens. Cyclophosphamide further amplified acute CIA when combined with doxorubicin, with reported incidence up to 93%. In contrast, capecitabine and vinorelbine were consistently associated with lower alopecia incidence. Importantly, CIA was not uniformly reversible. Persistent CIA (pCIA) occurred in up to 67% of patients treated with doxorubicin-based regimens and nearly 50% of those receiving docetaxel combinations, substantially higher than historically reported. Despite its high frequency and potential permanence, CIA remains underreported in oncology trials and insufficiently addressed in survivorship care. Recognizing CIA as both an acute toxicity and a potential long-term survivorship concern underscores the need for standardized reporting, longitudinal follow-up, and development of effective preventive strategies in breast cancer care.

1 March 2025 in Cutis
Verified
Journal Article
Closed access
GBGabriela Beraja
Gabriela Beraja

3 October 2024 in Journal of Cutaneous and Aesthetic Surgery
Verified
Journal Article
Open access
GBGabriela Beraja
Gabriela Beraja
VBVictor Beraja
Victor Beraja
Patients with eyebrow ptosis often remove their natural eyebrow hairs and tattoo the skin above the brow in their desired position. Frequently, these tattooed brows are drawn significantly higher than their actual anatomical location, resulting in an artificial appearance. By extending the incision laterally into the temporal region and meticulously undermining the subcutaneous tissue beneath the eyebrow, supraciliary, and temporal regions, we can effectively correct ptosis and achieve the creation of more esthetically pleasing tattooed brows.